Adenomatous polyposis coli
Drug research and approvals for adenomatous polyposis coli: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 17 studies of adenomatous polyposis coli are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 17
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL)NCT07726771 · Not applicable · London North West Healthcare NHS Trust · starts Jul 9, 2026
- Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal CarcinomaNCT07463599 · Phase 1 / Phase 2 · HonorHealth Research Institute · starts Feb 17, 2026
- Duodenal Polyposis Classification in FAPNCT07199127 · Not reported · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · starts Feb 2, 2018
- Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisNCT06950385 · Phase 3 · Rapamycin Holdings Inc. · starts Jul 18, 2025
- Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)NCT06641310 · Not applicable · University of Michigan Rogel Cancer Center · starts May 13, 2026
- Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis…NCT06614738 · Not reported · Hospices Civils de Lyon · starts Dec 17, 2024
- TPST-1495 in Patients With Familial Adenomatous PolyposisNCT06557733 · Phase 2 · National Cancer Institute (NCI) · starts Mar 31, 2026
- Ten Versus Fifteen Centimeter Pouch in IPAA SurgeryNCT06538402 · Not applicable · Odense University Hospital · starts Jul 3, 2025
- FOG-001 in Locally Advanced or Metastatic Solid TumorsNCT05919264 · Phase 1 / Phase 2 · Parabilis Medicines, Inc. · starts May 23, 2023
Approved 1
- CelecoxibCyclooxygenase-2 inhibitor
Phase 3 8
- SulindacCyclooxygenase inhibitor
- EflornithineOrnithine decarboxylase inhibitor
- Icosapent
- Soybean oil
- CalcitriolVitamin D receptor agonist
- AspirinCyclooxygenase inhibitor
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- Calcium carbonate
Phase 2 12 of 13
- SirolimusFK506-binding protein 1A inhibitor
- Curcumin
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- UrsodiolBile acid receptor FXR agonist
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- Fluticasone propionateGlucocorticoid receptor agonist
- NiclosamideDNA inhibitor
- Lactobacillus acidophilusProbiotic
- Hypromellose
Phase 1 or earlier 4
- Obeticholic acidBile acid receptor FXR agonist
- BevacizumabVascular endothelial growth factor A inhibitor
- TAK-733Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- GuselkumabInterleukin-23 inhibitor
How its trials ended
82 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 25 whose ending is known, 32% met their primary endpoint, 16% missed it and 52% stopped early.
- Ongoing2733%
- Completed, result not reported1822%
- Status unknown1215%
- Stopped: other or unclear1113%
- Met its primary endpoint810%
- Missed its primary endpoint45%
- Stopped: lack of efficacy11%
- Stopped: safety11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Feb 14, 1994 | ExisulindFor the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli. | OSI Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA